Table 4.
Patient # | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
---|---|---|---|---|---|---|---|---|
PD modality | CAPD | CAPD→APD | CAPD | CAPD | CAPD | CAPD | CAPD | CAPD |
Outcome | Continue | Continue | Continue | Transferred | Deceased | Continue | Continue | Continue |
Total follow-ups (mo) | 159 | 131 | 86 | 7 | 13 | 17 | 21 | 6 |
6-month average F VIII infusion before PD | Data unavailable | Data unavailable | 0 | 0 | NAa | 108 IU/d | 94 IU/d | NAa |
6-month average F VIII infusion after PD | 33 IU/d | 68 IU/d | 0 | 0 | NAa | 266 IU/d | 301 IU/d | NAa |
Days per hemorrhage episode 1 year before PD | Data unavailable | Data unavailable | NAb | NAb | NAc | 127 | 77 | NAc |
Days per hemorrhage after PDd | 167 | 165 | 2395 | NAb | NAc | 76 | 90 | NAc |
Hemoperitoneum after PD | 0 | 2 | 1 | 0 | 0 | 0 | 2 | Data unavailable |
6-month average Hgb before PD (g/l) | 105 | 78 | 81 | 85 | 78 | 94 | 89 | 67 |
6-month average Hgb after PD (g/l)e | 111 | 111 | 147 | 112 | 112.5 | 118 | 78 | 112 |
Average peritonitis rates (mo) | 159 | 33 | 17 | 7 | 13 | 17 | 21 | Data unavailable |
Average peritonitis rates of corresponding controlf (mo) | 77 | 56 | 71 | 69 | 68 | 69 | 69 | 68 |
Tunnel exit infection (counts) | 4 | 4 | 4 | 1 | 3 | 0 | 2 | 0 |
Most recent CCr l/w 1.73 m2 | 62.4 | 52.01 | 37.5 | 97.3 | 51.2 | 94.1 | 61.8 | 76.6 |
Most recent KT/V | 1.93 | 1.77 | 1.50 | 2.14 | 1.61 | 2.71 | 1.65 | 1.97 |
Most recent nPCR g/kd.d | 0.90 | 0.57 | 0.93 | 0.83 | 0.64 | 0.95 | 0.78 | 0.95 |
Most recent rGFR ml/min | 0 | 0 | 0 | 5.85 | 1.63 | 6.18 | 0.78 | 3.05 |
Most recent UF (ml/d) | 900 | 1200 | 2400 | 500 | 1050 | 180 | 450 | −200 |
Most recent Urine (ml/d) | 0 | 0 | 0 | 1250 | 550 | 1350 | 350 | 1500 |
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; F VIII, coagulation factor III; Hgb, hemoglobin; PD, peritoneal dialysis; UF, ultrafiltration.
Acquired HA.
No significant hemorrhage event was noticed in the previous year.
Incomparable due to improvement in F VIII inhibitors.
One year or longest possible follow-up duration, whichever shorter.
Or longest possible follow-up duration, whichever shorter.
Compared to patients of the same age group in general male PD patients.